U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. CDER Small Business & Industry Assistance (SBIA)
  5. Webinar: Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards - Oct. 11, 2019
  1. CDER Small Business & Industry Assistance (SBIA)

Webinar: Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards - Oct. 11, 2019

Follow us on LinkedIn

Download Slides

The purpose of this webinar is to provide information on the plans, progress, and technical specifications on enhancements to electronic submission of premarket and postmarket Individual Case Safety Reports (ICSRs) in FAERS using ICH E2B(R3) standards. This webinar will enhance the pharmaceutical industry’s knowledge of the processes needed to implement ICH E2B(R3) into their systems.

We encourage our participants to review the webcast videos, presentations, and transcripts from the March 25, 2019, and July 17, 2019, public meetings ahead of time.

TOPICS COVERED

  • FAERS II and E2B R3 Up Versioning Plans
    • Describe the objective, scope and timeline of E2B R3 regional implementation
  • E2B(R3) Regional Data Elements
    • Premarket safety reporting regional requirements
    • Postmarket safety reporting regional requirements
    • Postmarket combination product regional requirements
  • Updates on electronic submission routing mechanisms
    • Describe the different routing mechanisms to submit via ESG or Safety Reporting Portal
  • Testing ICH E2B (R3) Regional XML files
    • Describe the methods to test ICH E2B (R3) regional XMLs

INTENDED AUDIENCE

  • Pharmacovigilance experts focused on implementing safety databases and submitting safety reports to regulatory agencies
  • Regulatory affairs professionals who submit premarket safety reports
  • Consultants working to implement ICH E2B (R3) standards

FDA SPEAKER

Suranjan De, MS, MBA
Deputy Director
Regulatory Science Staff (RSS) | Office of Surveillance & Epidemiology | CDER | FDA

LEARNING OBJECTIVES

  • Understand FDA’s regional data elements for the implementation of ICH E2B(R3).
  • Enhance the pharmaceutical industry’s knowledge of the processes needed to implement ICH E2B(R3) and regional data elements into their systems.
Back to Top